Stem cell research may hold key to restoring neural function in glaucoma patients

Article

At this time there is no therapy that can restore vision after retinal ganglion cell (RGC) death in patients with glaucoma. However, stem cell-based treatments do have the potential to restore function in individuals with various neurodegenerative diseases, reported Keith R. Martin, MD, of Cambridge University, Cambridge, England, at the annual meeting of the Association for Research in Vision and Ophthalmology.

Recent Videos
Cassandra Gorsuch, PhD, chief scientific officer at Precision
Cassandra Gorsuch, PhD, chief scientific officer at Precision
Linda Marbán, PhD, the CEO of Capricor Therapeutics
Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio
Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
Related Content
Matthew Alexander, PhD

Exploring New Pathways in Muscular Dystrophy Research: From Fibrosis to Function

Marco Meglio
April 30th 2025
Article

Matthew Alexander, PhD, a neuromuscular expert, discussed the evolving landscape of targeted therapies in muscular dystrophies, from fibrosis and glycosylation to combination strategies with gene therapy.

ImmunoLogic

ImmunoLogic, Episode 3: "Breaking the Brain’s Barrier: CAR T-Cells Take on Glioblastoma" With Marcela Maus, MD, PhD

Joseph A. Fraietta, PhD;Janna Minehart, MD;Marcela V. Maus, MD, PhD;Noah Stansfield;Matt Hoffman
April 8th 2025
Podcast

In Episode 3 of ImmunoLogic, Marcela Maus, MD, PhD, discussed her research on CAR-T for treating glioblastoma.

Linda Marbán, PhD, the CEO of Capricor Therapeutics

Evaluating Capricor’s Cardiomyopathy Cell Therapy Deramiocel for DMD

Linda Marbán, PhD;Noah Stansfield
April 28th 2025
Article

Linda Marbán, PhD, the CEO of Capricor Therapeutics, discussed clinical data presented at MDA’s 2025 meeting.

ImmunoLogic

ImmunoLogic, Episode 2: "Charting New Frontiers in CAR T-Cell Safety" With Bruce Levine, PhD

Joseph A. Fraietta, PhD;Janna Minehart, MD;Noah Stansfield;Matt Hoffman
March 11th 2025
Podcast

In Episode 2 of ImmunoLogic, Bruce Levine, PhD, discussed the current the risk-benefit-ratio for CAR-T therapy.

BrainChild Bio's Pediatric Brain Tumor CAR-T BCB-276 Reels in Breakthrough Therapy Designation

BrainChild Bio's Pediatric Brain Tumor CAR-T BCB-276 Reels in Breakthrough Therapy Designation

Noah Stansfield
April 25th 2025
Article

The FDA’s decision was supported by data indicating overall survival benefit for patients with brain tumors from the phase 1 BrainChild-03 clinical trial.

UniQure's Huntington Disease Gene Therapy AMT-130 Snags FDA Breakthrough Therapy Designation

UniQure's Huntington Disease Gene Therapy AMT-130 Snags FDA Breakthrough Therapy Designation

Noah Stansfield
April 24th 2025
Article

Notably, AMT-130 has previously been granted regenerative medicine advanced therapy, orphan drug, and fast track designations by the agency.

© 2025 MJH Life Sciences

All rights reserved.